title: Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction.
abstract: Four hundred seventy-three patients with acute myocardial infarction (AMI) were treated with either saruplase (80 mg/hour, n = 236) or alteplase (100 mg every 3 hours, n = 237). Comedication included heparin and acetylsalicylic acid. Angiography was performed at 45 and 60 minutes after the start of thrombolytic therapy. When flow was insufficient, angiography was repeated at 90 minutes. Coronary angioplasty was then performed if Thrombolysis In Myocardial Infarction (TIMI) trial 0 to 1 flow was seen. Control angiography was at 24 to 40 hours. Baseline characteristics were similar. Angiography showed comparable and remarkably high early patency rates (TIMI 2 or 3 flow) in both treatment groups: at 45 minutes, 74.6% versus 68.9% (p = 0.22); and at 60 minutes 79.9% versus 75.3% (p = 0.26). Patency rates at 90 minutes before additional interventions were also comparable (79.9% and 81.4%). Angiographic reocclusion rates were not significantly different: 1.2% versus 2.4% (p = 0.68). After rescue angioplasty, angiographic reocclusion rates of 22.0% and 15.0% were observed. Safety data were similar for both groups. Thus, (1) early patency rates were high for saruplase and alteplase treatment, (2) reocclusion rates for both drugs were remarkably low, and (3) complication rates were similar. Thus, saruplase seems to be as safe and effective as alteplase.
authors.affiliation: Department of Cardiology, University Hospital Maastricht, The Netherlands.
authors.forename: F W
authors.initials: FW
authors.lastname: Bär
authors.forename: J
authors.initials: J
authors.lastname: Meyer
authors.forename: F
authors.initials: F
authors.lastname: Vermeer
authors.forename: R
authors.initials: R
authors.lastname: Michels
authors.forename: B
authors.initials: B
authors.lastname: Charbonnier
authors.forename: K
authors.initials: K
authors.lastname: Haerten
authors.forename: M
authors.initials: M
authors.lastname: Spiecker
authors.forename: C
authors.initials: C
authors.lastname: Macaya
authors.forename: M
authors.initials: M
authors.lastname: Hanssen
authors.forename: M
authors.initials: M
authors.lastname: Heras
authors.forename: J P
authors.initials: JP
authors.lastname: Boland
authors.forename: M C
authors.initials: MC
authors.lastname: Morice
authors.forename: F G
authors.initials: FG
authors.lastname: Dunn
authors.forename: R
authors.initials: R
authors.lastname: Uebis
authors.forename: C
authors.initials: C
authors.lastname: Hamm
authors.forename: O
authors.initials: O
authors.lastname: Ayzenberg
authors.forename: G
authors.initials: G
authors.lastname: Strupp
authors.forename: A J
authors.initials: AJ
authors.lastname: Withagen
authors.forename: W
authors.initials: W
authors.lastname: Klein
authors.forename: J
authors.initials: J
authors.lastname: Windeler
authors.forename: G
authors.initials: G
authors.lastname: Hopkins
authors.forename: H
authors.initials: H
authors.lastname: Barth
authors.forename: M J
authors.initials: MJ
authors.lastname: von Fisenne
mesh_terms: D000368:Aged; D004311:Double-Blind Method; D005060:Europe / Q000453:epidemiology; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D010960:Plasminogen Activators / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012008:Recurrence; D015912:Thrombolytic Therapy / Q000379:methods* / Q000706:statistics & numerical data; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; C067551:saruplase